Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today that it will be presenting the results from its ICH compliant Phase II study of MRX-4 (n=105) in patients suffering from allergic rhinitis at the upcoming 29th EAACI Congress (European Academy of Allergy and Clinical Immunology) in London on June 7th.
Atox Bio is an Israeli Biotechnology company that develops therapeutics for diseases mediated by an excessive inflammatory response.
Yissum introduces Dralgo, a novel computational platform for accelerated discovery of promising drug candidates. The new technology will be presented by its inventor, Professor Amiram Goldblum from the Institute of Drug Research at the Hebrew University of Jerusalem, on Tuesday, June 15 at the Technology Transfer Session II of the ILSI Biomed Israel 2010 conference, to be held at the David Intercontinental Hotel, Tel Aviv, Israel.
The pursuit of machine intelligence means we have to come up with ways to communicate with our computers in a way both entities can understand. But while computers process verbal commands in a straightforward fashion, humans tend to use more sophisticated speech forms, employing slang or symbols to convey an idea. So an Israeli research team has developed a machine algorithm that can recognize sarcasm.
BriefCam’s Video Synopsis – the technology that enables users to browse hours of video in minutes – was named “CCTV System Product of the Year”
The technology, invented by Dr. Raanan Fattal from the Hebrew University's School of Computer Science and Engineering, is called Edge Avoiding Wavelets and it enables better and faster detail enhancement and preserves edges when sharpening digital images.
Yissum also said that, together with the Technion Research and Development Foundation (TRDF), the technology transfer arm of the Technion Israel Institute of Technology, it will exclusively license to Avraham the commercial rights of Ladostigil, a novel cholinesterase, brain-selective monoamine oxidase inhibitor and europrotective agent for treatment of Alzheimer's disease and other neurodegenerative diseases. The drug has proven to be safe and well tolerated in Phase I/IIa clinical trials.
A single gene discovered by Hebrew University and US researchers Prof. Dani Zamir, Dr. Uri Krieger and Dr. Zach Lippman promises to produce tomatoes – one of Israelis’ favorite vegetables – in dramatically higher yields and with better taste. The discovery was patented by Yissum, HU’s technology transfer arm, which is seeking partners for further development and commercialization.
Anew IP management software system called TTM (Technology Transfer Management), recently installed at Yissum, the tech transfer company of the Hebrew University of Jerusalem, has made a dramatic difference in the company’s marketing efforts.
"We find various ways to bridge the financial gap over the "Valley of Death": bringing our projects to a valid proof of concept."
The PRX-105 program is being conducted in collaboration with Professor Hermona Soreq, from the Hebrew University in Jerusalem, Israel, a world leader in the field of acetylcholinesterase research, and based on patents that were licensed to Protalix Ltd. by Yissum.
In an interview to “La Nacion”, one of the most important daily newspapers of Latin America, said Prof. Mandler: “I think that if we can convince our respective Ministers of Science to establish an institutional partnership between Argentina and Israel, both countries could benefit. For Mandler and his host, Dr. Ernesto Calvo, Director of the Institute of Physical Chemistry of Materials, Environment and Energy (Inquimae), a collaboration of this type could help join forces in the increasingly competitive arena of world science. Among his various researchs, Mandler developed a way to deposit thin layers of silicon hydroxide: "He invented a very practical way to coat stents [devices to shore up the wall arteries] explains Dr. Calvo. And we realized that we have a method to see in real time how this deposition occurs. We were not planning to make any experiment this month, but we tested it and now we have results which we could publish in a major international magazine. None of us could have done this work separately."
The novel system monitors people's movements and use of open space to provide accurate data for use in healthcare, urban planning, retail yield management, law enforcement and tourism management. The technology was developed by Dr. Noam Shoval and Michal Isaacson, of the Hebrew University’s Department of Geography.
Yissum and Makhteshim will work together on two projects. The first collaboration is for the development of a novel method for producing slow and controlled release of herbicides. The second collaboration involves a novel insecticidal preparation combining a proprietary Chitin synthesis inhibitor (CSI) and a pathogenic fungus that kills caterpillars of night-flying moths, which are major pests for agriculture worldwide.
Oral drug delivery developer Chiasma has granted Novartis an option to obtain exclusive worldwide rights to develop and commercialize its Transient Permeability Enhancer (TPE) technology.
Roche signes a collaboration agreement with Yissum and selected six projects for further research.
Fulcrum's technology was invented by Professor Oded Shoseyov and Professor Arie Altman both from the Robert H. Smith Faculty of Agriculture, Food & Environment at The Hebrew University of Jerusalem, and was licensed to Fulcrum for further development, by Yissum, the technology transfer arm of the Hebrew University.
EtoCleanTM, is a new antiviral hand sanitizer which has been found to be highly effective against the swine flu virus. The novel product was invented by Professor Elka Touitou from the School of Pharmacy, at the Hebrew University of Jerusalem and is being developed by Novel Therapeutic Technologies (NTT), a spin-off company of Yissum.
The technology, involving isolation of the stem cells from bone marrow, was developed by Dr. Zulma Gazit, Dr. Gadi Pelled, Prof. Dan Gazit and their research team at the University's Skeletal Biotechnology Laboratory, and was licensed by YIssum to US-based TheraCell Inc.
Phase I data demonstrate that Protexia(R), based on research by HUJI Prof. Hermona Soreq, is safe and well tolerated with no evidence of immunogenicity. Suggest the potential for Protexia(R) as valuable countermeasure for nerve agent exposure.